一分钟看懂
这是一项关于小细胞肺癌的II 期研究，登记的药物或干预包括PF-08634404；Chemotherapy，当前状态为招募中。登记地点显示中国北京、福州、郑州、武汉等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
PF-08634404；Chemotherapy · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- Fujian Cancer Hospital · 福州
- Henan Cancer Hospital · 郑州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- The First Affiliated Hospital of Nanchang University · 南昌
- Shanghai Chest Hospital · 上海
- The first Affiliated Hospital, Zhejiang University School of Medicine · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Male or female participants aged ≥18 years at the time of informed consent.
- * Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
- * Participants have not received systemic therapy for T-SCLC.
- * Have at least one measurable lesion as the target lesion based on RECIST v1.1.
- * Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
- * Eastern Cooperative Oncology Group performance status of 0 or 1.
- * Have a minimum life expectancy of \>12 weeks.
- * Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07476287；登记信息更新于 2026-09-28；本站同步于 2026-10-08，中国中心当前名额未经人工确认。